Movement Alert｜PegBio Intraday Decline 8.11%, Profit-Taking Emerges After Rani Therapeutics Partnership Rally

Market Focus13:29

On July 14, PegBio (02565.HK) declined 8.11% in regular trading, trading at HKD 5.91/share, with turnover of HKD 121 million. The pullback follows a sharp rally driven by the company's memorandum of understanding with Nasdaq-listed Rani Therapeutics announced on July 8.

The stock had surged approximately 29% on July 10 and gained another 4% on July 13 after the two companies agreed to leverage Rani's proprietary RaniPill oral biologics delivery platform for oral formulation screening and preclinical development of PegBio's obesity and metabolic disease candidates. The partnership also covers potential R&D, manufacturing, and commercialization cooperation outside China under a three-year framework.

The current decline reflects concentrated profit-taking following the rapid cumulative gains. Market enthusiasm has moderated as participants reassess the timeline, noting the collaboration remains in its early screening phase with a lengthy path ahead before any substantive clinical advancement or commercialization milestones materialize.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164934874?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 13:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164934874","market":"hk","top_or_hot":-1,"title":"Movement Alert｜PegBio Intraday Decline 8.11%, Profit-Taking Emerges After Rani Therapeutics Partnership Rally","media":"Market Focus","content":"<p><p>On July 14, PegBio (02565.HK) declined 8.11% in regular trading, trading at HKD 5.91/share, with turnover of HKD 121 million. The pullback follows a sharp rally driven by the company's memorandum of understanding with Nasdaq-listed Rani Therapeutics announced on July 8.</p><p>The stock had surged approximately 29% on July 10 and gained another 4% on July 13 after the two companies agreed to leverage Rani's proprietary RaniPill oral biologics delivery platform for oral formulation screening and preclinical development of PegBio's obesity and metabolic disease candidates. The partnership also covers potential R&D, manufacturing, and commercialization cooperation outside China under a three-year framework.</p><p>The current decline reflects concentrated profit-taking following the rapid cumulative gains. Market enthusiasm has moderated as participants reassess the timeline, noting the collaboration remains in its early screening phase with a lengthy path ahead before any substantive clinical advancement or commercialization milestones materialize.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PegBio Intraday Decline 8.11%, Profit-Taking Emerges After Rani Therapeutics Partnership Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PegBio Intraday Decline 8.11%, Profit-Taking Emerges After Rani Therapeutics Partnership Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-14 13:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 14, PegBio (02565.HK) declined 8.11% in regular trading, trading at HKD 5.91/share, with turnover of HKD 121 million. The pullback follows a sharp rally driven by the company's memorandum of understanding with Nasdaq-listed Rani Therapeutics announced on July 8.</p><p>The stock had surged approximately 29% on July 10 and gained another 4% on July 13 after the two companies agreed to leverage Rani's proprietary RaniPill oral biologics delivery platform for oral formulation screening and preclinical development of PegBio's obesity and metabolic disease candidates. The partnership also covers potential R&D, manufacturing, and commercialization cooperation outside China under a three-year framework.</p><p>The current decline reflects concentrated profit-taking following the rapid cumulative gains. Market enthusiasm has moderated as participants reassess the timeline, noting the collaboration remains in its early screening phase with a lengthy path ahead before any substantive clinical advancement or commercialization milestones materialize.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1164934874","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164934874","pubTimestamp":1784006953,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 14, PegBio (02565.HK) declined 8.11% in regular trading, trading at HKD 5.91/share, with turnover of HKD 121 million. The pullback follows a sharp rally driven by the company's memorandum of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"走势警报|PegBio 盘中下跌 8.11%，Rani Therapeutics Partnership 反弹后出现获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On July 14, PegBio (02565.HK) declined 8.11% in regular trading, trading at HKD 5.91/share, with turnover of HKD 121 million. The pullback follows a sharp rally driven by the company's memorandum of understanding with Nasdaq-listed Rani Therapeutics announced on July 8.The stock had surged approximately 29% on July 10 and gained another 4% on July 13 after the two companies agreed to leverage Rani's proprietary RaniPill oral biologics delivery platform for oral formulation screening and preclinical development of PegBio's obesity and metabolic disease candidates. The partnership also covers potential R&D, manufacturing, and commercialization cooperation outside China under a three-year framework.The current decline reflects concentrated profit-taking following the rapid cumulative gains. Market enthusiasm has moderated as participants reassess the timeline, noting the collaboration remains in its early screening phase with a lengthy path ahead before any substantive clinical advancement or commercialization milestones materialize.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164934874","isCrawlerRequest":true}